Neonatal Hypertension Differential Diagnoses
- Author: Joseph Flynn, MD, MS; Chief Editor: Ted Rosenkrantz, MD more...
Diagnostic Considerations
Cardiac conditions to consider in the differential diagnosis of neonatal hypertension include thoracic aortic coarctation. Renovascular conditions to consider in the differential diagnosis include the following:
- Thromboembolism
- Renal artery stenosis
- Midabdominal aortic coarctation
- Renal venous thrombosis
- Compression of renal artery
- Idiopathic arterial calcification
- Congenital rubella syndrome
Renal parenchymal diseases to consider in the differential diagnosis of neonatal hypertension include the following:
- Polycystic kidney disease
- Multicystic dysplastic kidney disease
- Tuberous sclerosis
- Ureteropelvic junction obstruction
- Acute tubular necrosis
- Cortical necrosis
- Interstitial nephritis
- Hemolytic-uremic syndrome
Pulmonary conditions to consider in the differential diagnosis of neonatal hypertension include the following:
- Bronchopulmonary dysplasia
- Pneumothorax
Endocrine conditions to consider in the differential diagnosis of neonatal hypertension include the following:
- Congenital adrenal hyperplasia
- Hyperaldosteronism
- Hyperthyroidism
- Pseudohypoaldosteronism type II
Medications/intoxications to consider in the differential diagnosis of neonatal hypertension include the following:
- Dexamethasone
- Adrenergic agents
- Vitamin D intoxication
- Theophylline
- Caffeine
- Pancuronium
- Phenylephrine
- Maternal cocaine or heroin use
Tumors that should be considered in the differential diagnosis of neonatal hypertension include the following:
- Neoplasia
- Wilms tumor
- Mesoblastic nephroma
- Neuroblastoma
- Pheochromocytoma
Neurologic conditions to consider in the differential diagnosis of neonatal hypertension include the following:
- Pain
- Intracranial hypertension
- Seizures
- Familial dysautonomia
- Subdural hematoma
Miscellaneous conditions to consider in the differential diagnosis of neonatal hypertension include the following:
- Closure of abdominal wall defect
- Adrenal hemorrhage
- Hypercalcemia
- Traction
- Extracorporeal membrane oxygenation
- Birth asphyxia
- Urologic neoplasms
Differential Diagnoses
- Extremely Low Birth Weight Infant
- Graves Disease
- Hematuria
- Infantile Polyarteritis Nodosa
- Noonan Syndrome
- Posterior Urethral Valves
- Prematurity
- Respiratory Distress Syndrome
- Turner Syndrome
- Williams Syndrome
Singh HP, Hurley RM, Myers TF. Neonatal hypertension. Incidence and risk factors. Am J Hypertens. Feb 1992;5(2):51-5. [Medline].
Friedman AL, Hustead VA. Hypertension in babies following discharge from a neonatal intensive care unit. A 3-year follow-up. Pediatr Nephrol. Jan 1987;1(1):30-4. [Medline].
Blowey DL, Duda PJ, Stokes P, Hall M. Incidence and treatment of hypertension in the neonatal intensive care unit. J Am Soc Hypertens. Sep 17 2011;[Medline].
Neal WA, Reynolds JW, Jarvis CW, Williams HJ. Umbilical artery catheterization: demonstration of arterial thrombosis by aortography. Pediatrics. Jul 1972;50(1):6-13. [Medline].
Abman SH, Warady BA, Lum GM, Koops BL. Systemic hypertension in infants with bronchopulmonary dysplasia. J Pediatr. Jun 1984;104(6):928-31. [Medline].
Alagappan A, Malloy MH. Systemic hypertension in very low-birth weight infants with bronchopulmonary dysplasia: incidence and risk factors. Am J Perinatol. Jan 1998;15(1):3-8. [Medline].
Seliem WA, Falk MC, Shadbolt B, Kent AL. Antenatal and postnatal risk factors for neonatal hypertension and infant follow-up. Pediatr Nephrol. Dec 2007;22(12):2081-7. [Medline].
Zubrow AB, Hulman S, Kushner H, Falkner B. Determinants of blood pressure in infants admitted to neonatal intensive care units: a prospective multicenter study. Philadelphia Neonatal Blood Pressure Study Group. J Perinatol. Nov-Dec 1995;15(6):470-9. [Medline].
Pejovic B, Peco-Antic A, Marinkovic-Eric J. Blood pressure in non-critically ill preterm and full-term neonates. Pediatr Nephrol. Feb 2007;22(2):249-57. [Medline].
Kent AL, Kecskes Z, Shadbolt B, Falk MC. Normative blood pressure data in the early neonatal period. Pediatr Nephrol. Sep 2007;22(9):1335-41. [Medline].
Dionne JM, Abitbol CL, Flynn JT. Hypertension in infancy: diagnosis, management and outcome. Pediatr Nephrol. Jan 2012;27(1):17-32. [Medline].
Dionne JM, Abitbol CL, Flynn JT. Erratum to: Hypertension in infancy: diagnosis, management and outcome. Pediatr Nephrol. Jan 2012;27(1):159-60. [Medline].
Task Force on Blood Pressure Control in Children. Report of the Second Task Force on Blood Pressure Control in Children--1987. Task Force on Blood Pressure Control in Children. National Heart, Lung, and Blood Institute, Bethesda, Maryland. Pediatrics. Jan 1987;79(1):1-25. [Medline].
Crossland DS, Furness JC, Abu-Harb M, et al. Variability of four limb blood pressure in normal neonates. Arch Dis Child Fetal Neonatal Ed. Jul 2004;89(4):F325-7. [Medline].
Brierley J, Marks SD. Treating the causes of paediatric hypertension using non-invasive physiological parameters. Med Hypotheses. May 3 2010;[Medline].
| Postconceptual Age | 50th Percentile | 95th Percentile | 99th Percentile |
| 44 weeks | |||
| SBP | 88 | 105 | 110 |
| DBP | 50 | 68 | 73 |
| MAP | 63 | 80 | 85 |
| 42 weeks | |||
| SBP | 85 | 98 | 102 |
| DBP | 50 | 65 | 70 |
| MAP | 62 | 76 | 81 |
| 40 weeks | |||
| SBP | 80 | 95 | 100 |
| DBP | 50 | 65 | 70 |
| MAP | 60 | 75 | 80 |
| 38 weeks | |||
| SBP | 77 | 92 | 97 |
| DBP | 50 | 65 | 70 |
| MAP | 59 | 74 | 79 |
| 36 weeks | |||
| SBP | 72 | 87 | 92 |
| DBP | 50 | 65 | 70 |
| MAP | 57 | 72 | 77 |
| 34 weeks | |||
| SBP | 70 | 85 | 90 |
| DBP | 40 | 55 | 60 |
| MAP | 50 | 65 | 70 |
| 32 weeks | |||
| SBP | 68 | 83 | 88 |
| DBP | 40 | 55 | 60 |
| MAP | 49 | 64 | 69 |
| 30 weeks | |||
| SBP | 65 | 80 | 85 |
| DBP | 40 | 55 | 60 |
| MAP | 48 | 63 | 68 |
| 28 weeks | |||
| SBP | 60 | 75 | 80 |
| DBP | 38 | 50 | 54 |
| MAP | 45 | 58 | 63 |
| 26 weeks | |||
| SBP | 55 | 72 | 77 |
| DBP | 30 | 50 | 56 |
| MAP | 38 | 57 | 63 |
| Drug | Class | Intravenous (IV) Dosage | Comments |
| Esmolol | Beta blocker | 100-300 mcg/kg/min IV infusion | Very short acting; constant IV infusion necessary |
| Hydralazine | Vasodilator (arteriolar) | 0.15-0.6 mg/kg/dose IV bolus or 0.75-5mcg/kg/min IV constant infusion | Tachycardia is frequent adverse effect; must administer every 4 hours when administered as IV bolus |
| Labetalol | Alpha blocker and beta blocker | 0.2-1 mg/kg/dose IV bolus or 0.25-3 mg/kg/h IV constant infusion | Heart failure, bronchopulmonary dysplasia (BPD), relative contraindications |
| Nicardipine | Calcium channel blocker | 1-5 mcg/kg/min IV constant infusion | May cause reflex tachycardia |
| Sodium nitroprusside | Vasodilator (arteriolar and venous) | 0.5-10 mcg/kg/min IV constant infusion | Thiocyanate toxicity can occur with prolonged use (>72 h) or in renal failure; usual maintenance dose is below 2 mcg/kg/min; may use 10 mcg/kg/min for short duration (ie, < 10-15 min) |
| Drug | Class | Oral Dosage | Comments |
| Captopril | Angiotensin-converting enzyme (ACE) inhibitor | Under age 3 months: 0.01-0.5 mg/kg/dose 3 times daily; not to exceed 2 mg/kg/day At or above age 3 months: 0.15-0.3 mg/kg/dose 3 times daily; not to exceed 6 mg/kg/day | Monitor serum creatinine and potassium levels |
| Clonidine | Central agonist | 0.05-0.1 mg/dose 2-3 times daily | Adverse effects include dry mouth and sedation; rebound hypertension with abrupt discontinuation |
| Enalapril | ACE inhibitor | 0.08-0.6 mg/kg/day, given once or twice daily | Monitor serum creatinine and potassium levels |
| Hydralazine | Vasodilator (arteriolar) | 0.25-1 mg/kg/dose 3-4 times daily; not to exceed 7.5 mg/kg/day | Suspension stable up to 1 wk; tachycardia and fluid retention are common adverse effects; lupuslike syndrome may develop in slow acetylators |
| Isradipine | Calcium channel blocker | 0.05-0.15 mg/kg/dose 4 times daily; not to exceed 0.8 mg/kg/d or 20 mg/day | Suspension may be compounded; useful for both acute and chronic hypertension |
| Amlodipine | Calcium channel blocker | 0.1-0.3 mg/kg/dose twice daily; not to exceed 0.6 mg/kg/d or 20 mg/d | Less likely to cause sudden hypotension than isradipine |
| Minoxidil | Vasodilator (arteriolar) | 0.1-0.2 mg/kg/dose 2-3 times daily | Most potent oral vasodilator; excellent for refractory hypertension |
| Propranolol | Beta-blocker | 0.5-1 mg/kg/dose 3 times daily | Maximal dose depends on heart rate; may administer as much as 8-10 mg/kg/d if no bradycardia; avoid in infants with BPD |
| Labetalol | Alpha and beta blocker | 1 mg/kg/dose 2-3 times daily, up to 12 mg/kg/d | Monitor heart rate; avoid in infants with BPD |
| Spironolactone | Aldosterone antagonist | 0.5-1.5 mg/kg/dose twice daily | Potassium-sparing diuretic; monitor electrolytes; several days necessary to observe maximum effectiveness |
| Hydrochlorothiazide | Thiazide diuretic | 2-3 mg/kg/d orally every day or divided twice daily | Monitor electrolytes |
| Chlorothiazide | Thiazide diuretic | 5-15 mg/kg/dose twice daily | Monitor electrolytes |

